The company is having a "breakthrough" with its cholesterol drug. Its other drug, Eylea, was just approved by the Food and Drug Administration following positive Phase III results, according to TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio.
It's cholesterol treatment is the world's first alternative to statin drugs, which many people are allergic too, he said.
Biotechnology stocks continue to move higher, while large-cap pharmaceutical stocks remain stagnant amid slower growth.
-- Written by Bret Kenwell in Petoskey, Mich.
At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.